Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement ... 5.3% of the control group (P=0.003); new permanent pacemakers were implanted in 17.4% and 2.3% ...

A new study published in the New England Journal of Medicine showed that improvements in symptoms and quality of life were ...

TCT 943: Durable Valve Prosthesis Performance and Sustained Symptom Relief: 2-Year Outcomes Following Transseptal Transcatheter Mitral Valve Replacement in the HighLife TSMVR Feasibility Study Receive ...

Compared with SAVR, TAVR was associated with an increased likelihood of needing a pacemaker and moderate-to-severe paravalvular leaks. Notably, on a prespecified analysis, the study addressed the ...

The child who underwent device closure along with pacemaker implantation developed pacing lead endocarditis after four ... our study with a large number of patients shows the safety of transcatheter ...

TTVR also led to "near elimination" of the TR, as 99.1% of people had moderate or less TR (and 95.3% mild or less) at the ...

A new study published in the Journal of American Medical Association showed that the upper-extremity route for secondary ...

In another milestone for the Alchemist Hospital,sector 21 Panchkula, the Cardiac Team did the first successful Transcatheter Aortic Valve Replacement (TAVR). The procedure was performed by Dr.

Jenscare Scientific Co., Ltd. ('Jenscare' or the 'Company') (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR ...